Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report. - Wikidata - wikimedia - TriplyDB

Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.

Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.

http://www.wikidata.org/entity/Q37591461

about

Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.

http://www.wikidata.org/entity/Q37591461

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.

@en

Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.

@nl

type

label

Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.

@en

Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.

@nl

prefLabel

Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.

@en

Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.

@nl

P1433

Q37591461-286E38A8-A512-4ED0-8D46-8281C9583CA9

P1476

Q37591461-9D86AF6F-45AD-42AB-B74A-29E897016B24

P2093

Q37591461-1C45A0F2-3DD7-48B4-A8AA-74A131215FBF

Q37591461-5B7FB06A-EADD-43D5-83F5-D5860CB13DAF

Q37591461-AC8386B7-0526-4AF6-9C8C-24F06C7FAE0D

Q37591461-E1C21F1A-EFCC-4995-A881-EF0CA3375E5E

P2860

Q37591461-034F0FA5-6D24-4176-8D37-AC341C42C9E6

Q37591461-4DE28DE0-1FA1-4ED0-AD36-8F0749F901B2

Q37591461-50CF2A76-9045-4D3C-889B-1A2FAA1BAB22

Q37591461-568D6B72-726E-41FE-B1AA-E445E4B6EAB7

Q37591461-78B84E32-03CF-4BF1-9D4D-DFABE274CB6A

Q37591461-85A9FAC0-F571-439D-AB28-98C97E15C38B

Q37591461-87F57168-F64A-459E-A251-F862743BE2AA

Q37591461-90946123-6698-4B7C-B0CE-330247A83256

Q37591461-AA570A21-8F79-4483-AE36-38FDF4558A5D

Q37591461-C4DC4D70-7D61-4491-849A-9FCD896840E1

P304

Q37591461-0B6CDB11-19E4-4049-85C3-3BEFB2E9F663

P31

Q37591461-720985C7-1C4B-4A43-ACC3-046B3E250C07

P356

Q37591461-C53FD96A-5861-408C-BF70-6A34B4AE640A

P433

Q37591461-61BA8E38-6E01-4EEC-AABA-2AA708BA6DF3

P478

Q37591461-8A0F307E-4C08-46BB-A1BE-2797EC95A4E4

P577

Q37591461-BC6CEEA4-B9B4-40BC-9B77-FEFF27D480D5

P5875

Q37591461-05D82AD8-BFB4-47EF-9AAA-B2F93E1B4055

P698

Q37591461-196CA9F6-78BC-48CC-9C88-1E491752D8E9

P921

Q37591461-4EB7D52E-0A71-4DD0-B6BC-211563E4F3C2

P932

Q37591461-1F18AFE0-4365-437D-BAAE-527021565A56

P356

P1433

Cancer Biology and Therapy

P1476

Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.

@en

P2093

Fei-fei Teng

http://www.w3.org/2001/XMLSchema#string

Jian-dong Zhang

http://www.w3.org/2001/XMLSchema#string

Jin-ming Yu

http://www.w3.org/2001/XMLSchema#string

Xue Meng

http://www.w3.org/2001/XMLSchema#string

P2860

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib

P304

172-177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CBT.27221

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259246796

http://www.w3.org/2001/XMLSchema#string

P698

24316558

http://www.w3.org/2001/XMLSchema#string

P921

P932

3928132

http://www.w3.org/2001/XMLSchema#string